Author | Mark Ball, MD | OncLive

Author | Mark Ball, MD


Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14, 2016


Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.